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Abstract
 
Systemic autoimmune disease is frequently characterized by the production of autoantibodies
against widely expressed intracellular self-antigens, whereas B cell tolerance to ubiquitous and highly
expressed extracellular antigens is strictly enforced. To test for differences in the B cell response to
intracellular and extracellular self-antigens, we sequestered a tolerogenic cell surface antigen intra-
cellularly by addition of a two amino acid endoplasmic reticulum (ER) retention signal. In
contrast to cell surface antigen, which causes the deletion of autoreactive B cells, the intracellu-
larly sequestered self-antigen failed to induce B cell tolerance and was instead autoimmunogenic.
The intracellular antigen positively selected antigen-binding B cells to differentiate into B1 cells
and induced large numbers of IgM autoantibody-secreting plasma cells in a T-independent manner.
By analyzing the impact of differences in subcellular distribution independently from other variables,
such as B cell receptor affinity, antigen type, or tissue distribution, we have established that intra-
cellular localization of autoantigen predisposes for autoantibody production. These findings help
explain why intracellular antigens are targeted in systemic autoimmune diseases.
Key words: SLE • autoimmunity • self tolerance • B lymphocytes • hen egg lysozyme
 
Introduction
 
Our understanding of the mechanisms responsible for B
cell tolerance has been largely established in a series of
experiments using mice expressing Ig transgenes, encoding
antibodies directed against naturally occurring or neo self-
antigens. These studies have established that tolerance to
abundant systemic extracellular antigens occurs by deleting
(1–3), editing (4, 5), or inactivating (6–8) the autoreactive
B cells, whereas B cells that bind low avidity or rare antigens
may remain functionally ignorant (9, 10). This spectrum of
tolerogenic or neutral responses is well described in transgenic
mice expressing different forms of the foreign protein hen
egg lysozyme (HEL) (11). Self-reactive B cells expressing
transgenic Ig receptors for HEL (MD4 anti-HEL Ig [Ig
 
HEL
 
])
undergo deletion or receptor editing in the BM when
they encounter systemic membrane-bound HEL (mHEL)
expressed on the cell surface under the class I promoter (1,
12). Ig
 
HEL
 
 B cells that encounter abundant but lower avidity
soluble HEL (sHEL) at a level in excess of 10–20 ng/ml
enter the repertoire but are held in a potentially reversible
state of functional inactivation called anergy (7, 8, 13, 14)
and have a shortened life span which is largely due to their
inability to compete with other B cells (15, 16). Ig
 
HEL
 
 B
cells that encounter sHEL below the level of 10 ng/ml retain
the functional characteristics of naive B cells and have
therefore been described as immunologically ignorant (9).
Deficiency in negative regulators of B cell receptor (BCR)
signaling, such as the coreceptor CD22, src-kinase Lyn, or
phosphatase SHP1, lowers the threshold for tolerance and
causes Ig
 
HEL
 
 B cells to be deleted rather than anergized by
abundant sHEL (17–19). In contrast, deficiency in positive
regulators, such as coreceptors CD19 or CD45, raises the
threshold for tolerogenic responses (20, 21). Together, the
transgenic and genetic experiments have led to a widely
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accepted signal strength model of tolerance in which the
fate of an autoreactive B cell is determined by the abun-
dance and avidity of its target self-antigen and the affinity
of its BCR (11).
When immunological tolerance to systemic antigens
breaks down, as in systemic lupus erythematosus (SLE), au-
toantibodies are characteristically produced against a wide
range of intracellular targets (22). Under these circum-
stances, factors other than signal strength may be critical in
deciding the fate of autoreactive cells. Despite good evi-
dence that a breakdown in tolerance to intracellular anti-
gens is a key feature of systemic autoimmune disease, it has
not been determined if the mechanisms maintaining B cell
tolerance against intracellular and extracellular antigens are
the same. Intracellular antigens targeted in different sys-
temic autoimmune diseases are frequently grouped to-
gether in cell surface blebs on apoptotic cells, where they
may perhaps give rare but high avidity stimulation to au-
toreactive B cells (23). Furthermore, several of the lupus
susceptibility genes identified in animal models are in-
volved in the clearance or sequestration of cellular debris
and these intracellular targets (24). In familial human SLE
due to C1q deficiency, the primary defect lesion seems
likely to be due to reduced phagocytic clearance of apop-
totic or necrotic cells (25, 26). These observations raise the
possibility that there may be fundamental differences in B
cell tolerance to intracellular self-antigens compared with
those on the cell surface.
Because most of the autoantigens targeted in SLE are in-
tracellular, we have set out to test the mechanisms acting to
maintain self-tolerance to intracellular antigens. Using a
newly generated panel of transgenic mice expressing an in-
tracellularly sequestered variant of mHEL (ER-restricted
mHEL [mHEL-KK]) we demonstrate that intracellular se-
questration alone is sufficient to convert the tolerogenic
self-antigen into a potent autoimmunogen. Whereas cell
surface antigen causes the deletion or receptor editing of
immature B cells, intracellular antigen induces autoanti-
bodies and the differentiation of B1 B cells. These findings
show that the cellular location of self-antigen is a critical
factor in determining the positive and negative selection of
autoreactive B cells, and they provide a basis for under-
standing the selective targeting of intracellular antigens by
autoantibodies in SLE.
 
Materials and Methods
 
Generation of mHEL-KK Mice.
 
The transgene was prepared
by adapting the previously described mHEL-expressing KLK
construct (1). A modified H-2K
 
b
 
 transmembrane region in-
cluding a dilysine-retention motif was produced by PCR am-
plification of the original KLK construct. The forward primer (5
 
 
 
to 3
 
 
 
: ccagggtcgcctggcgcaacc) encodes the junction between the
3
 
 
 
 sequence of the lysozyme gene and the 5
 
 
 
 H-2K
 
b
 
 transmem-
brane sequence. The reverse primer (5
 
 
 
 to 3
 
 
 
: ccatgcggccgctgtct-
tcaatccctcttaccctttttaccagtccttctcatcttcatcacaaaagcc) encodes a
NotI site and the dilysine retention motif derived from human
UDP-glucuronosyltransferase 2B4 as a 5
 
 
 
 tag (27), with the 3
 
 
 
end priming off the H-2K
 
b
 
 transmembrane sequence. The 265-
bp PCR product was digested with XhoI and NotI, subcloned
into pBluescript, and checked for fidelity by sequencing. To al-
low directional cloning, the pKLK H-2K
 
b
 
 transmembrane 3
 
 
 
XhoI restriction site was destroyed and a NotI site created via
the introduction of an oligonucleotide linker (pKLK
 
 
 
linker).
The final construct was obtained by digesting pKLK
 
 
 
linker
with XhoI and NotI and ligating it to the 196-bp XhoI-NotI
PCR fragment. The mHEL-KK transgene was excised by diges-
tion with SalI and ClaI and prepared for microinjection into
(C57BL/6 
 
 
 
 CBA/CaJ)F1 oocytes as described previously (8).
Transgenic founders were identified by PCR and Southern
blotting. Animals were kept in SPF conditions. The animal ex-
periments were approved by the Oxford University Ethical Re-
view Committee and were performed under Home Office li-
cence.
 
Immunohistochemistry.
 
Organs were snap-frozen in liquid ni-
trogen and stored at –20
 
 
 
C until sectioning. Cryostat sections (7
 
 
 
m) were cut, fixed, and stained as described previously (28) with
the addition of a blocking step before the first primary antibody.
Sections were blocked with 5% normal goat serum (Vector
Laboratories) in tris-buffered saline (TBS) for 30 min at room
temperature. Expression of HEL was detected by incubating with
unpurified rabbit polyclonal anti-HEL serum followed by alkaline-
phosphatase–conjugated anti–rabbit IgG (Sigma-Aldrich). Plasma
cells and metallophillic macrophages were detected with synde-
can-1 (BD Biosciences) and MOMA-1 (Serotec), respectively,
and biotinylated goat anti–rat IgG (Serotec). Each was then fol-
lowed with StreptABComplex/AP (Dako). Biotinylated AMS9.1
or B220 and StreptABComplex/HRP (Dako) were used to detect
B cells. Enzyme reactions were developed with either DAB (Vec-
tor Laboratories) for peroxidase or Fast Red/Napthol AS-MX or
Vector Blue (Vector Laboratories) for alkaline phosphatase. Sec-
tions were counterstained with hematoxylin.
 
Confocal Microscopy.
 
All steps were performed at room tem-
perature. Frozen sections were fixed with 4% paraformaldehyde/
250 mM Hepes for 10 min and then 8% paraformaldehyde/
Hepes for 50 min. After washing with PBS, sections were
quenched with 50 mM NH
 
4
 
Cl for 5 min and washed in PBS.
Sections were then permeabilized with 0.1% Triton X-100/PBS
for 10 min and washed in PBS and then in TBS. Sections were
blocked with normal goat serum as for immunohistochemistry
and washed with TBS. To stain for HEL expression, slides were
incubated with rabbit anti-HEL serum for 30 min, washed with
TBS, and incubated with goat anti–rabbit IgG-TRITC (Jackson
ImmunoResearch Laboratories) for 30 min. Images were col-
lected using the 568-nm line of a krypton-argon laser on a Bio-
Rad Laboratories MRC1024 confocal scanning laser microscope.
A 40
 
 
 
 objective (NA 1.3) was used; images were collected using
Lasersharp 2000 software with Kallman averaging and histogram
stretched to fill an 8-bit intensity range. No further image pro-
cessing was applied.
 
Flow Cytometry.
 
BM and spleen suspensions were stained, as
described previously (8), with the following mAbs: IgM
 
a
 
, DS-1–
phycoerythrin (PE; BD Biosciences); IgD
 
a
 
, AMS9.1-fluorescein
isothiocyanate (FITC); B220, 6B2-allophycocyanin (APC; Caltag),
6B2-PE (Caltag), and 6B2-FITC; class II, I-A
 
p
 
–FITC (BD Bio-
sciences); Mac-1–FITC (Caltag); CD21-biotin (Bi) followed by
streptavidin-PE (Caltag); CD9-Bi, (BD Biosciences) followed by
streptavidin-APC (Caltag); IgM
 
a
 
-Bi, (BD Biosciences) followed
by streptavidin-tricolor (Tc; Caltag); and CD21-FITC, CD23-PE,
CD69-FITC, and CD86-PE (BD Biosciences). HEL binding cells
were detected by incubating cells with 200 ng/ml unlabeled HELT
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(Sigma-Aldrich) followed by the anti-HEL mAb HyHEL9-Tc or
HyHEL9-FITC. All analysis was performed using a FACSCalibur
flow cytometer and Cell Quest software (Becton Dickinson).
 
Quantification of Serum HEL Concentration.
 
Splenocytes (10
 
5
 
)
from an Ig
 
HEL
 
 transgenic mouse (MD4; a gift from C. Goodnow,
Australian National University, Canberra, Australia) were incu-
bated on ice for 45 min with either HEL serially diluted in nor-
mal mouse serum or serum alone, followed by staining with
HyHEL9-Tc and B220-FITC as for flow cytometry. A standard
curve of the mean HyHEL9-Tc fluorescence of positively stain-
ing B cells versus the concentration of HEL was plotted. The
concentration of serum HEL in the mHEL-KK transgenic lines
was determined by incubating Ig
 
HEL
 
 cells with mHEL-KK serum
and comparing the mean fluorescence with the standard curve.
 
Measurement of Receptor Occupancy.
 
BM cells from Ig
 
HEL
 
 and
Ig
 
HEL
 
/mHEL-KK mice were incubated on ice for 20 min with
either serially diluted concentrations of HEL in staining media
containing 0.1% sodium azide or media alone, followed by stain-
ing with HyHEL9-Tc as for flow cytometry. Receptor occu-
pancy was determined as described previously (9).
 
Measurement of Serum Anti-HEL IgM
 
a
 
 and Splenic IgM
 
a
 
-secreting
Plasma Cells.
 
Anti-HEL IgM
 
a
 
 was measured from sera by ELISA
as described previously (16). Anti-HEL IgM
 
a
 
-secreting cells were
measured in spot ELISA in 96-well plates coated with 1 mg/ml
HEL in carbonate buffer, pH 9.8. Spots of bound antibody were
revealed with biotinylated anti-IgM
 
a
 
 (DS-1; BD Biosciences) fol-
lowed by avidin-alkaline phosphatase (Sigma-Aldrich).
 
In Vitro Culture.
 
Splenocytes from Ig
 
HEL
 
, Ig
 
HEL
 
/mHEL-KK,
or Ig
 
HEL
 
/sHEL transgenic mice (sHEL ML5 mice; a gift from C.
Goodnow, Australian National University) were harvested at
room temperature in 10% complete medium (comprising
RPMI supplemented with 10% FCS, 10 mM Hepes, 2 mM glu-
tamine, 50 
 
 
 
M 2-mercaptoethanol) washed once and resus-
pended. 5 
 
 
 
 10
 
6
 
 cells were incubated at 37
 
 
 
C in 5% CO
 
2
 
 in
0.25 ml of complete medium with 0.5 
 
 
 
g/ml HEL. Control
cells were held on ice without antigen. After 17 h, cells were
analyzed by flow cytometry for surface expression of CD69 and
CD86 (B7.2).
 
Cell Lysates and Western Blot Analysis.
 
Splenocytes for stimu-
lation from Ig
 
HEL
 
, Ig
 
HEL
 
/mHEL-KK, or Ig
 
HEL
 
/sHEL transgenic
mice were isolated in 10% complete medium at room tempera-
ture, washed, and resuspended in medium. Prior to stimulation,
both cells and stimulant were warmed for 5 min at 37
 
 
 
C, and re-
actions were initiated by combining them in a ratio of 3:1, which
gave instant mixing. Stimuli were medium alone for 3 min in the
case of all unstimulated samples or HEL for 3 min (final concen-
tration 1 
 
 
 
g/ml). Reactions were terminated by transferring cells
into an equal volume of ice cold 2
 
 
 
 NP-40 lysis buffer (compo-
sition of 1
 
 
 
 lysis buffer: 1% NP-40, 50 mM Tris, pH 8.0, 150
mM sodium chloride, 5 mM EDTA, 10 mM sodium fluoride, 10
mM 
 
 
 
-glycerol phosphate, 2 mM PMSF, and 10 
 
 
 
l/ml of the
Sigma-Aldrich protease-inhibitor cocktail I and phosphatase-
inhibitor cocktails I and II). After 15 min on ice, the samples
were centrifuged at 13,000 
 
g 
 
at 4
 
 
 
C for 20 min, the supernatants
added to 2
 
 
 
 SDS-PAGE reducing sample buffer, and boiled for 5
min before loading onto 10% SDS-polyacrylamide gels. Western
blots were probed with antiphosphotyrosine (Mab 4G10; Upstate
Biotechnology) followed by HRP–anti–mouse IgG (Upstate
Biotechnology) or rabbit polyclonal anti-Lyn anti-CD79
 
 
 
 or
anti-CD79
 
 
 
 (gifts from J. Cyster, University of California San
Francisco, San Francisco, CA) followed by HRP–goat anti–rabbit
(Zymed Laboratories). Detection was by enhanced chemilumi-
nescence (Amersham Biosciences).
 
Fetal Liver Chimeras.
 
Fetal liver cells were harvested at day
19 of gestation from embryos expressing the Ig
 
HEL
 
 transgene, and
0.5 
 
 
 
 10
 
7
 
 cells were injected into the lateral tail vein of mHEL-
KK and nontransgenic recipients that had been lethally irradiated
with two doses of 5 Gy gamma irradiation separated by 3 h. The
animals received antibiotics (amoxycillin 0.25 mg/ml in water
bottles) for the first 3 wk of their reconstitution and were killed
at 8 wk.
 
Results
 
Transgenic Mice Expressing HEL as a Ubiquitous Intracellular
Self-antigen.
 
To study the mechanisms involved in main-
taining tolerance to intracellular self-antigens, we modified
the tolerogenic cell surface mHEL construct by adding a
dilysine ER retention motif to the COOH-terminal cyto-
plasmic tail (mHEL-KK; Fig. 1) (29). Proteins carrying di-
lysine or other dibasic motifs bind to cytosolic COP I pro-
teins, which causes their continuous and avid retrieval from
the golgi to the ER (30). Apart from the cytoplasmic tail,
the mHEL and mHEL-KK constructs were identical and
shared the same ubiquitous class I promoter, extracytoplas-
mic lysozyme domain, and transmembrane segment. Three
lines of transgenic mice carrying the ER-restricted HEL
were produced using fertilized eggs from (CBA
 
 
 
C57BL/
6)F1 mice and backcrossed six generations to C57BL/6.
The transgenic lines, designated mHEL-KK1, mHEL-
KK2, and mHEL-KK3, were healthy and bred normally.
Histological examination of fixed and permeabilized spleen
and thymus showed expression in many cells with a typical
ER distribution on confocal microscopy (Fig. 2, A and B).
Flow cytometric analysis for cell surface and intracellular
antigen in spleen and BM cells with anti-HEL antibodies
confirmed that expression was intracellular (Fig. 2 C). In
each organ sample preparation there were a minority of
cells that were positive for surface-exposed HEL, ranging
from 0.015% lymphocytes in BM to 0.4% in spleen samples
(Fig. 2 D), but these were membrane-permeable necrotic
or late stage apoptotic cells as determined by staining with
propidium iodide (not depicted). In transgenic mice ex-
pressing mHEL on the cell surface, sHEL is present in se-
rum at levels in excess of 200 ng/ml due to proteolytic
cleavage from the intact protein (unpublished data). In the
mHEL-KK lines, sHEL was present in a range of 2–10 ng/
Figure 1. Generation of a transgene expressing a ubiquitous intracellular
membrane-bound lysozyme. Derived from the construct used to express
mHEL on the cell surface (KLK) (1), the sole modification is the addition
of a dilysine ER reteintion motif to the cytoplasmic tail (black box). In
other respects, the constructs are identical, including the lysozyme domain
and the H-2Kb transmembrane region. Restriction sites: X, XhoI; N,
NotI; S, SalI; C, ClaI.T
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ml, which would be compatible with release from cellular
debris or rare surface expression (Fig. 2 E).
 
Intracellular HEL Antigen Fails To Induce Either Deletion or
Anergy.
 
To study the fate of B cells specific for the intra-
cellular HEL autoantigen, mHEL-KK mice were crossed
with MD4 Ig
 
HEL
 
 transgenic mice carrying Ig heavy and light
chain transgenes encoding high affinity IgM
 
a
 
 and IgD
 
a
 
 spe-
cific for HEL (8). The resulting Ig
 
HEL
 
/mHEL-KK double
transgenic mice were of normal appearance, bred normally,
and their survival up to 200 d was no different from single
or nontransgenic littermates. Histological analysis of heart,
lung, liver, LN, spleen, skin, kidney, and thymus showed
no difference between transgenics and littermate controls.
Mild peribronchial inflammation and focal lobular hepatitis,
described previously as affecting the C57BL/6 strain (31),
was neither affected by the presence of the transgene nor as-
sociated with known pathogens (unpublished data). Flow
cytometric analysis showed similar numbers of immature
HEL-binding B cells in the BM and mature HEL-binding B
cells in the spleen of Ig
 
HEL
 
 single transgenic and Ig
 
HEL
 
/
mHEL-KK double transgenic mice (Table I). A small re-
duction of mature follicular cells was seen in the mesenteric
LNs and BM of double transgenics (Table I). Importantly,
there was no evidence of the extreme IgM antigen receptor
down-regulation or deletion of immature B cells in the BM
that characterizes acquisition of tolerance to surface-dis-
played mHEL (1) (Fig. 3 A and Table I).
By flow cytometry, only 7.19% (95% confidence: 5.63–
8.75%) of antigen receptors on immature B cells were oc-
cupied with cleaved sHEL, values below that previously
shown to be necessary for anergy induction in B cells from
Ig
 
HEL
 
/sHEL (ML5) double transgenics (Fig. 3 C) (7–9, 13).
Figure 2. Transgenic mice expressing HEL as a ubiquitous intra-
cellular self-antigen. (A) Immunohistochemistry of permeabilized
spleen cryostat sections from nontransgenic (non) and mHEL-KK1
transgenic (mHEL-KK) mice stained for expression of HEL (red).
Position of B cell follicle (FO) is shown. (B) Confocal microscopy of
permeabilized mHEL-KK1 thymocytes, showing HEL staining in
the endoplasmic reticulum (ER) and in a nuclear pore (NP) within
the nucleus (N). (C) Histograms of BM and spleen cells from non-Tg
(dotted line), mHEL-KK1 (thin line) and mHEL mice (KLK3; thick
line) stained for surface HEL. (D) The percentage of unpermeabilized
mHEL-KK1 ( ) and non-Tg lymphocytes ( ) that are positive for
surface HEL. (F) Serum lysozyme concentrations in mHEL-KK lines.
 
Table I.
 
Effect of Intracellular Antigen on Central and Peripheral B Cell Numbers
 
Bone marrow Spleen Mesenteric lymph node
Immature B cells Mature B cells  HEL-binding B cells
 
10
 
5
 
10
 
5
 
10
 
5
 
Ig 13.01 (
 
n
 
 
 
 
 
 29) 9.71 (
 
n
 
 
 
 
 
 29) 261.30 (
 
n
 
 
 
 
 
 31) 50.83 (
 
n
 
 
 
 
 
 25)
mHEL-KK Dbl 13.53 (
 
n
 
 
 
 
 
 18) 3.72 (
 
n
 
 
 
 
 
 18) 206.31 (
 
n
 
 
 
  21) 28.07 (n   15)
P   0.5749 P   0.0021 P   0.1748 P   0.0257
Numbers shown are the means of the different populations, and n is the number of mice in each group. Immature and mature B cells in the BM are
defined as HEL-binding IgMa /IgDa  and IgMa /IgDa , respectively. The mean age of the IgHEL transgenic (Ig-Tg) mice was 77.66 d (SD 28.37)
and IgHEL/mHEL-KK double transgenic (Dbl-Tg) 69.06 d (SD 23.29), with an overall range of 43–166 d. Statistical comparison was by an ANOVA
test, with count as dependent variable, and genotype and each experiment as explanatory variables using STATA™ version 7.0. No significant effect
of age or sex was detected.T
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The phenotype of developing and mature B cells in the
double transgenic mice was also consistent with subthresh-
old exposure to soluble self-antigen. In comparison to an-
ergic B cells in IgHEL/sHEL (ML5) double transgenics, the
B cells in IgHEL/mHEL-KK double trangenics showed only
modest down-regulation of IgM and HEL binding (Fig. 3,
A and D), little reduction in CD21 (Fig. 3 B), and no in-
duction of MHC class II (Fig. 3 D). Levels of CD23, B7.2
(CD86), and B220 were normal (Fig. 3, B and D and not
depicted). Transitional and follicular B cell populations
were preserved in IgHEL/mHEL-KK double trangenics
(Fig. 3, B and F), but there was a marked reduction in the
CD21hi, CD23int/lo marginal zone population, which was
confirmed by histological analysis (Table I and Fig. 3 E). A
similar but more marked reduction in B cells in the splenic
marginal zones is also observed in IgHEL/sHEL double
transgenic mice (Fig. 3 B) (28). In both cases, the loss of
marginal zone cells may represent either developmental ar-
rest or continuous depopulation of the marginal zone in re-
sponse to antigen binding as described after immunization
with soluble and particulate antigens (32, 33).
To demonstrate the absence of B cell anergy in IgHEL/
mHEL-KK double transgenics, we performed a series of
functional tests comparing B cells from the IgHEL/mHEL-
KK mice with anergic B cells from IgHEL/sHEL double
transgenic mice and naive B cells from IgHEL single trans-
genic mice. After overnight culture with antigen, B cells
from IgHEL/mHEL-KK mice up-regulated both CD69 and
CD86 (B7.2) to normal levels (Fig. 4 A) and showed no
block in the proximal BCR signaling (Fig. 4 B), in contrast
to anergic cells from IgHEL/sHEL double transgenics.
Intracellularly Derived HEL Autoantigen Triggers Autoanti-
body Production. In striking contrast to IgHEL mice express-
ing cell surface or soluble forms of HEL autoantigen (1, 7, 8,
34), mice expressing intracellular HEL autoantigen con-
tained high autoantibodiy titers and large numbers of au-
toantibody-secreting plasma cells (Fig. 5, A and B). Com-
pared with IgHEL single transgenic mice, IgHEL/mHEL-KK
Figure 3. The development of conventional B cells in the presence of intracellular membrane-bound lysozyme. (A) Flow cytometry of BM and spleen
B cells from IgHEL (Ig, top row A–C, and E), IgHEL/mHEL-KK (mHEL-KK Dbl, middle row A–C, and E) and IgHEL/sHEL (sHEL Dbl, bottom row A–C)
transgenic mice gated on B220 and stained with antibodies to IgMa and IgDa (representative of all mice in Table I). (B) Flow cytometry of splenic B cells
from Ig and mHEL-KK Dbl and sHEL Dbl transgenic mice gated on B220 and stained with antibodies to CD23 and CD21. (C) Flow cytometry of lympho-
cytes from Ig and mHEL-KK Dbl and sHEL Dbl transgenic BM stained with HEL/HyHEL9 (thick line) or Hy9Tc (thin line). (D) Flow cytometry of
splenic B cells from Ig (thin line), mHEL-KK Dbl (thick line), and sHEL Dbl (dotted line) stained with antibodies to MHC class II, CD69, B7.2 (CD86),
and HEL/HyHEL9. (E). Spleen sections from Ig and mHEL-KK Dbl mice stained with antibodies to B220 (brown) and metallophillic macrophages
(blue). Positions of B cell follicles (FO), metallophillic macrophages (M ), and marginal zone B cells (MZ) are shown. (F). Percentage of splenic B cell
populations from Ig (n   12, white bars) and mHEL-KK Dbl transgenics (n   11, black bars) gated as shown in B: transitional cells CD21loCD23lo (TR),
follicular CD21intCD23hi (FO), and marginal CD21hiCD23int-lo (MZ).T
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double transgenic mice contained 25-fold more plasma cells
secreting anti-HEL IgM in the spleen and an equivalent in-
crease in anti-HEL IgM antibodies in the serum. This corre-
sponds to an elevation in serum antibody of  10,000 fold
compared with mice expressing HEL as a cell surface au-
toantigen (1). Histological examination of IgHEL/mHEL-KK
double transgenic spleens showed numerous plasma cells
confined to the red pulp cords (Fig. 5 C). Increased numbers
of HEL-specific plasma cells were not found in the BM or
LNs (Fig. 5 B). A similar increase in autoantibody titers was
found in all three mHEL-KK lines. To test whether autoan-
tibody production was T cell dependent, IgHEL/mHEL-KK
mice were crossed onto a Rag2 /  background. The mean
number of plasma cells in the IgHEL Rag2 /  was 12,223 per
spleen (95% confidence: 0–33,930; n   4) and in IgHEL/
mHEL-KK  Rag2 /  was 297,267 per spleen (95% confi-
dence: 111,577–482,956; n   5). Therefore, in stark contrast
to mHEL or sHEL (1, 7, 8) the sequestered intracellular
HEL is immunogenic, inducing autoreactive plasma cells and
high titre autoantibodies in a T cell–independent manner.
Positive Selection of B1 Cells. The sequestered form of
mHEL-KK autoantigen also stimulated the B cells to form a
large population of partially activated cells in the peritoneal
cavity that have the characteristics of B1 cells (35, 36).
Whereas no cells of this type are formed in IgHEL transgenic
mice in the absence of antigen, nor in mice expressing
tolerogenic forms of secreted or mHEL, flow cytometry of
peritoneal cells from the IgHEL/mHEL-KK double trans-
genic mice showed two populations of HEL-binding B
cells: small B220hi, IgD , IgM-modulated, Mac1  cells typ-
ical of conventional B cells and large B220lo, IgD /lo, IgM-
bright, Mac1  CD9  cells characteristic of B1 cells (37)
(Fig. 6, A and B). The total number of peritoneal IgD /lo,
IgM-bright cells (gated as shown in Fig. 6 A) in IgHEL/
mHEL-KK mice was 6.4    104 cells (95% confidence:
2.86–9.96   104; n   13), compared with 1.45   104 cells
Figure 4. Absence of func-
tional inactivation in B cells from
IgHEL/mHEL-KK double trans-
genic mice. (A). Flow cytometry
of splenocytes from Ig and
mHEL-KK Dbl and sHEL Dbl
transgenic mice incubated for
17 h with 0.5  g/ml HEL (thick
line) or kept on ice as controls
(thin line) gated on B220 and
stained with CD69 or B7.2
(CD86). (B) Western blot analysis
of splenocytes from Ig and
mHEL-KK Dbl and sHEL Dbl
transgenic mice stimulated with
media alone or 1  g/ml HEL for
3 min, and stained with antibodies
to phosphotyrosine (4G10), lyn,
Ig  (CD79 ), and Ig  (CD79 ).
Results are representative of three
separate experiments.
Figure 5. Intracellular HEL autoantigen triggers autoantibody production. (A) Serum anti-HEL IgMa titers in Ig, mHEL-KK Dbl, and nontransgenic
(non) mice as determined by ELISA. Dots show geometric means, and bars represent the 95% confidence limits. The background is twice the level in
blank wells. (B) Anti-HEL IgMa-secreting plasma cells in BM, spleen, mesenteric LN (MLN), and submandibular LN (SMLN) of Ig (white bars) and
mHEL-KK Dbl mice (black bars). Columns show geometric means and bars represent the 95% confidence limits. (C) Spleen sections from Ig and
mHEL-KK Dbl mice stained with antibodies to IgDa B cells (brown) and plasma cells (red).T
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(95% confidence: 0.82–2.08   104; n   18) in the absence
of antigen (P   0.0013). The absence of CD5 expression on
the peritoneal cells indicated that the B1 cells were of the
B1b rather than B1a subtype (not depicted). Similar results
were found in all three mHEL-KK transgenic lines. The ac-
tivation and selection of B1 cells and the generation of natu-
ral antibodies is typically T independent (35), and we found
that the absence of T cells has no effect on the selection of
B1 cells induced by intracellular HEL (not depicted).
Autoimmunity and B1 Cell Selection Is Independent of Anti-
gen Expression in the B Cells. Because the intracellular an-
tigen is ubiquitous, it was a possibility that the observed
phenotypes could be due to cis effects of antigen, either
toxicity or by binding to the BCR, within the B cells. To
exclude this possibility, we reconstituted lethally irradiated
mHEL-KK and nontransgenic recipients with fetal liver
from IgHEL single transgenic donors and showed that anti-
HEL autoantibodies were still induced and large B220lo,
IgD /lo, IgM-bright, Mac1 , CD9  IgHEL B1 cells were
still positively selected in the mHEL-KK–expressing chi-
meras (Fig. 7; Table II; not depicted). This confirms that
the immunogenic effect of intracellular antigen on B cells
occurs in trans and that our findings will be applicable to
other intracellular antigens, which may be abundant but
not necessarily expressed in the lymphoid tissues.
Discussion
Our results establish that the fate of B cells reactive with
membrane-bound autoantigens is profoundly different de-
pending on whether the antigen is retained inside the cell
or displayed on the cell surface. In contrast to the elimina-
tion or receptor editing of B cells reacting with surface au-
toantigens, B cells reactive with an intracellular autoantigen
are not tolerized and are induced to form autoantibody-
secreting plasma cells and B1 cells. Because the BCR spec-
ificity and the autoantigen are identical in the different
model systems, we can state conclusively that differences in
the location of membrane antigens in the cell are sufficient
to cause these striking differences in B cell fate. These find-
Figure 6. Positive selection of B1 cells in the peritoneum. (A)
Flow cytometry of peritoneal lymphocytes from Ig and mHEL-KK
Dbl mice stained with antibodies to IgMa (IgMa-PE) and IgDa.
The elliptical gate indicates B1 cells and the percentage of B1 cells
in the lymphocyte gate. Plots are representative of  13 mice each.
(B) Histograms gated on all IgMa-high peritoneal lymphocytes (rect-
angular gate shown in A) forward scatter (FSC), B220, Mac-1, and
CD9 expression from Ig (thin lines) and mHEL-KK Dbl mice
(thick lines).
Table II. Numbers of HEL-binding B Cells in Lethally Irradiated Nontransgenic and mHEL-KK Transgenic Mice Reconstituted with IgHEL 
Fetal Liver
Bone marrow Spleen Mesenteric lymph node
Recipient Immature B cells Mature B cells HEL-binding B cells
105 105 105
Non (n   4) 18.10 9.30 213.62 22.69
mHEL-KK (n   3) 14.88 6.52 269.38 23.21
P   0.2702 P   0.0625 P   0.0686 P   0.9129
Numbers of HEL-binding B cells in lethally irradiated nontransgenic (Non) and mHEL-KK transgenic mice reconstituted with IgHEL fetal liver.
Numbers shown are the means of the different populations, and n is the number of mice in each group. Immature and mature B cells in the BM are
defined as HEL-binding IgMa /IgDa  and IgMa /IgDa , respectively. Mice were reconstituted for 42 d. Statistical comparison was by Student’s t
test using STATA™ version 7.0.T
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ings demonstrate that intracellular localization is a predis-
posing factor for causing an antigen to be a target of au-
toantibodies. In addition, the results contradict the widely
held view that the spectrum of B cell tolerance can be ex-
plained solely by the specificity, affinity, and avidity of in-
teractions between autoreactive B cells and self-antigen.
It is instructive to compare our results with other immu-
noglobulin transgenic models, some of which are also char-
acterized by the production of autoantibodies. B cells ex-
pressing   and   immunoglobulin transgenes against the
thymocyte cell surface antigen CD90 (Thy-1) also have a
conventional phenotype in the absence of self-antigen and
generate B1 cells and autoantibodies in its presence (38).
However, in contrast to our results the conventional anti-
CD90 B cells developing alongside B1 cells in the presence
of self-antigen are severely arrested, short lived, and func-
tionally inactive, CD21-negative, HSA-bright cells that
also express CD5, which may be a marker of anergy, and
there are no plasma cells in the spleen. The late negative se-
lection of the conventional anti-CD90 B cells may be due
to the abundance of CD90  T cells in the blood and their
paucity in the BM, since a similar phenotype of develop-
mental arrest and deletion is observed in immunoglobulin
transgenic B cells reactive with the T cell surface antigen
CD8 (39). The combination of peripheral deletion and B1
cell development also occurs in mice expressing an immu-
noglobulin transgene against an erythrocyte antigen. Au-
toreactive antierythrocyte B1 cells survive in the peri-
toneum where they produce autoantibodies that cause
hemolytic anemia; however, B cells are eliminated from
the blood, spleen, and LNs, where the antigen is abun-
dantly expressed (3). The results of these models support
the concept that B cell selection depends on the circum-
stances of antigen presentation and signal strength. How-
ever, the absence of antigen-negative controls or mice ex-
pressing different forms of the same antigen makes it
difficult to know to what extent positive selection is inde-
pendent of affinity, avidity, BCR, or unusual features of
the particular antigen in question. Indeed, the function of
CD90 is unknown and so it may play a specific role in B1
development. The critical advantage of the HEL model is
that it allows comparisons to be made in a series of mice
with well-characterized and carefully controlled differ-
ences, and it is this feature that has enabled us to identify
the role of antigen location in B cell selection. On the basis
of our findings, we think it is very likely that positive selec-
tion would be apparent in other Ig transgenic models di-
rected against naturally occurring intracellular self-antigens,
including DNA, if it were possible to compare affected
mice with antigen-negative controls and thus distinguish
this positive selection from immunological ignorance.
The selection of HEL-binding B1 B cells is a feature
unique to HEL transgenic mice expressing the intracellular
HEL autoantigen, since it does not occur in response to
any of the extracellular forms of the same protein. It has
been suggested that B1 cells represent a distinct lineage
characterized by a particular and limited repertoire of
BCRs (40, 41). Unlike conventional B cells, B1 cells ap-
pear to arise mainly but not exclusively in early ontogeny,
and together with marginal zone B cells their development
is IL-7 independent (42). They are capable of self-renewal,
and they do not require expression of the TNF family
ligand BAFF for continued survival (43, 44). The develop-
ment of B1 cells is increased in mice with increased BCR
signaling due to deficiencies in SHP1, CD22, and Lyn (18,
45–48) but absent from BCR signaling compromised
CD19- and btk-deficient animals (20, 49). Transgenic B
cells expressing higher levels of BCR are also more likely
to develop into B1 cells in the presence of their antigen
(50). These findings indicate a general requirement for in-
creased BCR signaling in B1 development, which may be
intrinsic to the receptor or generated by an interaction with
antigen. Our results confirm that commitment to the con-
ventional or B1 cell lineage is not necessarily predeter-
mined by the expression of a particular BCR. Instead, our
data suggests that the positive selection of the B1 cells is fa-
vored by rare encounters between immunogenic self-anti-
gen and a minority of immature B cells.
The origin of autoreactive plasma cells in the IgHEL/
mHEL-KK double transgenic mice is uncertain, since it is
possible that they arise from conventional B cells including
marginal zone B cells, B1 B cells, or both (Fig. 8). Experi-
ments using parabiotic mice have shown that B1 cells retain
the capacity to recirculate through the secondary lymphoid
organs (51), although they are Mac-1 negative and difficult
to distinguish from large B220lo, IgD /lo, IgM-bright tran-
Figure 7. Autoimmunity and
B1 cell selection is independent
of antigen expression on the B
cells. (A) Serum anti-HEL IgMa
titers in lethally irradiated non-
transgenic and mHEL-KK re-
cipients reconstuted with IgHEL
expressing fetal liver. Dots show
individual mice, and bars show
the geometric means. (B) Anti-
HEL IgMa-secreting plasma cells
in the spleens of nontransgenic
(white bars) and mHEL-KK re-
cipient mice (black bars). Columns
show geometric means, and bars represent the 95% confidence limits. (C) Flow cytometry of peritoneal lymphocytes from the chimeras stained with
antibodies to IgMa (IgMa-Bi) and IgDa. The box gate indicates the location of IgHEL B1 cells and the percentage of these cells in the lymphocyte gate.T
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sitional B cells. Therefore, IgHEL-specific B1 cells may dif-
ferentiate into autoreactive plasma cells in the spleen of the
mHEL-KK double transgenic mice (Fig. 8 B). Increased
splenic plasma cells and B1 cells are frequently found to-
gether in mice with exaggerated BCR signaling due to B
cell–specific mutations as, for example, in SHP1 deficiency
(18). The alternative possibility is that the anti-HEL plasma
cells derive from follicular B cells, which undergo T-inde-
pendent activation when they bind the high avidity multi-
valent intracellular self-antigen exposed on dying cells, or
from marginal zone B cells, since rapid differentiation into
plasma cells and relocation to the red pulp cords could in
part account for the reduced size of the marginal zone in
the IgHEL/mHEL-KK double transgenics (Fig. 8 A). Distin-
guishing between these possibilities is likely to require ge-
netics experiments targeted at the different cell populations.
The fact that autoreactive B cells are so exquisitely sus-
ceptible to elimination by even low affinity interactions
with surface-displayed membrane self-antigens (34, 52) im-
plies that additional factors such as timing, frequency, and
context must be critical in the autoimmune response to the
intracellular antigens. One key factor may be in the pres-
ence or absence of costimulation during autoantigen en-
counter (Fig. 8). Previous experiments have shown that
mHEL in combination with T cell costimuli (13) or LPS
(12) is a potent activator of IgHEL transgenic B cells and in-
ducer of antibody formation. In the mHEL-KK animals,
the ER-sequestered membrane antigen is displayed on dy-
ing cells, where it may similarly activate antibody forma-
tion. Since we have shown that T cells are not involved in
development of anti-HEL autoantibody-producing plasma
cells, another immunogenic costimulus may serve this role.
Candidates include CpG DNA, which is displayed extra-
cellularly on dying cells and activates B cells through Toll-
like receptor (TLR)9 (53) and possibly heat shock proteins,
which may also signal through TLRs (54, 55). In this con-
text, it is interesting to note that the generation of autoanti-
bodies and survival of peritoneal B1 cells in the anti-
erythrocyte Ig transgenic model depended up LPS from
pathogens or diet (56, 57). Therefore, it is possible that the
endogenous Toll-like receptor ligands on dying cells could
provide similar B cell costimulation in the absence of overt
infections. Mechanisms of this type may account for the
generation and targeting of autoantibodies against intracel-
lular ER and nuclear antigens that are clustered on the sur-
face of apoptotic cells, including histones and DNA (23).
The absence of overt autoimmune disease in the IgHEL/
mHEL-KK mice may be because the IgHEL MD4 transgene
only encodes IgM and IgD, whereas the majority of patho-
genic autoantibodies in SLE are of the IgG isotype; how-
ever, the appearance of disease may also require breakdown
in other checkpoints in B cell self-tolerance. Under these
circumstances, exaggerated positive selection by intracellu-
lar antigens would be the first step in a pathogenic process
leading to systemic autoimmunity. This could explain why
SLE occurs in the absence of factors such as c1q, Dnase1,
c-mer, and serum amyloid P, which are normally required
for the clearance of necrotic or apoptotic cells (25, 58–60).
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